Dermatology Made Easy is based on the most popular topics from DermNet NZ's vast array of material. The book combines the essential focus of the ‘Made Easy’ book series with the authority and knowledge base of DermNet NZ's unparalleled resources.
Author(s): Dr Jenny Chung, House Officer, Department of Dermatology, Auckland City Hospital, New Zealand. DermNet NZ. Editor-in-chief: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy Editor: Gus Mitchell, August 2017.
Pemphigoid nodularis is a rare nodular variant of bullous pemphigoid. There is limited literature on pemphigoid nodularis to date, with only case reports describing the condition. It was first described by Provost et al (1979) and Yung et al (1981) [1,2].
* Reproduced under Creative Commons Licensing, from Indian Dermatol Online J. 2014 Apr-Jun; 5(2): 189–192. doi: 10.4103/2229-5178.131101. PMC.
Pemphigoid nodularis is reported to be more common in women and elderly people.
The causes of this nodular type of bullous pemphigoid are unknown. One theory is that the nodules are induced by rubbing and scratching in individuals with subclinical bullous pemphigoid.
Patients with prurigo nodularis (nodular prurigo) may induce pemphigoid antibodies through physical trauma to the skin and basement membrane.
Pemphigoid nodularis presents with hyperkeratotic nodules and blisters, which are usually located on the extremities and trunk.
The nodules are similar to those seen in nodular prurigo. Pruritic papules or confluent plaques have also been reported.
Pemphigoid nodularis requires clinical or histological evidence of both pruritic nodules and blisters.
Histopathological features of pemphigoid nodularis include:
Blood tests may reveal positive indirect immunofluorescence and autoantibody titres to BP180 and BP230.
Pemphigoid nodularis can appear similar to nodular prurigo and other forms of prurigo. However, nodular prurigo lacks blisters and has no serum or immunofluorescence evidence of IgG to bullous pemphigoid antigens. Histology can be used to differentiate between the two conditions.
The treatment for pemphigoid nodularis can be challenging. Topical steroid therapy alone is inadequate.
Pemphigoid nodularis is treated with the following:
The prognosis of pemphigoid nodularis is uncertain. Older age and/or neurological comorbidities are associated with higher mortality rates.
See the DermNet NZ bookstore.
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.